All In Biotech

Drug Trial Radar · NCT07790120

A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of SAL0120 Tablets in Patients Uncontrolled Hypertension on Two or More Medications

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

256

Actual

Start

Oct 29, 2024

Primary completion

Jul 2, 2026

Study completion Jul 2, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, and effect of low, middle and high dose of SAL0120 versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 256 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).

Conditions

  • Uncontrolled Hypertension
  • Resistant Hypertension

Interventions

  • SAL0120Drug

    SAL0120 Administered orally, once daily (QD): Low dose, Middle dose, High dose

  • PlaceboDrug

    Placebo Administered orally, once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Seated Systolic Blood Pressure for low, middle and high dose of SAL0120Time frame: at Week 12
  2. Change From Baseline in Seated Systolic Blood Pressure for low, middle and high dose of SAL0120Time frame: At Week 4, 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.